Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2011

View Archived Issues

Additional data disclosed from ALLEGRO and BRAVO trials of laquinimod in RRMS

Initial treatment phase of rabeprazole trial in pediatric patients completed

Potential new target for MS therapy discovered at U.S. univeristy

Candidate vaccine for CDI-associated diarrhea is immunogenic and well tolerated

New therapeutic approach suggested for achalasia / News in Context

Pharmasset commences pivotal phase III program for interferon-free PSI-7977 regimen

Scientists at Amgen disclose new PI3K inhibitors

OncoTherapy Science patents novel PDZ-binding kinase inhibitors

Novel histone deacetylase inhibitors disclosed

AgonOx and MedImmune join to develop TNF receptor superfamily member 4 agonists

Array BioPharma and Genentech jointly synthesize new beta-secretase 1 inhibitors

Novel receptor-interacting protein 2 inhibitors prepared by GSK

Promising data disclosed from phase Ib trial of DB-959Na

Isis antisense drugs enter phase I development for type 2 diabetes

FDA sets PDUFA date for alogliptin and alogliptin/pioglitazone NDAs

Medivir reports final results from ASPIRE study

Furiex acquires exclusive license to develop MuDelta

FDA approves highly specific HPV assay

ExonHit extends strategic collaboration with Allergan

Resverlogix begins dosing in ASSURE study

FDA recommends approval of Vytorin in patients with predialysis chronic kidney disease

Meda files MAA for Dymista in Europe

Immunomedics resumes clivatuzumab tetraxetan study

Clonidine Lauriad receives European orphan drug status

Nuron Biotech starts phase III trial of NU-100 in MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...